ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1639
CHEMBL1639
Compound Name ALISKIREN
ChEMBL Synonyms ALISKIREN | TEKTURNA | RASILEZ | ALISKIREN FUMARATE | ALISKIREN HEMIFUMARATE | SPP100
Max Phase 4 (Approved)
Trade Names TEKTURNA | RASILEZ
Molecular Formula C30H53N3O6

Additional synonyms for CHEMBL1639 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC( ...
Download SMILES
Standard InChI InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21) ...
Download InChI
Standard InChI Key UXOWGYHJODZGMF-QORCZRPOSA-N

Sources

  • British National Formulary
  • FDA Approval Packages
  • HeCaToS Compounds
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL1639

Molecule Features

CHEMBL1639 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:N First In Class:Y Chirality:Single Stereoisomer Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Renin inhibitor Renin DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Atrial FibrillationD001281EFO:0000275atrial fibrillation3ClinicalTrials
Myocardial InfarctionD009203EFO:0000612myocardial infarction3ClinicalTrials
Glomerulonephritis, IGAD005922EFO:0004194IGA glomerulonephritis3ClinicalTrials
Diabetes MellitusD003920EFO:0000400diabetes mellitus3ClinicalTrials
Diabetes Mellitus, Type 2D003924EFO:0001360type II diabetes mellitus1ClinicalTrials
Diabetic NephropathiesD003928EFO:0000401diabetic nephropathy2ClinicalTrials
Essential HypertensionD000075222EFO:1002032primary hypertension3ClinicalTrials
Coronary Artery DiseaseD003324EFO:0000378coronary artery disease3ClinicalTrials
Marfan SyndromeD008382Orphanet:558Marfan syndrome3ClinicalTrials
Renal Insufficiency, ChronicD051436EFO:0003884chronic kidney disease1ClinicalTrials
HypertensionD006973EFO:0000537hypertension4ClinicalTrials
ClinicalTrials
DailyMed
DailyMed
DailyMed
AtherosclerosisD050197EFO:0003914atherosclerosis2ClinicalTrials
Diabetic RetinopathyD003930EFO:0003770diabetic retinopathy2ClinicalTrials
Heart FailureD006333EFO:0000373congestive heart failure3ClinicalTrials
Heart FailureD006333EFO:0003144heart failure3ClinicalTrials
Kidney DiseasesD007674EFO:0003086kidney disease2ClinicalTrials
Cardiovascular DiseasesD002318EFO:0000319cardiovascular disease4ATC

Clinical Data

ClinicalTrials.gov ALISKIREN
The Cochrane Collaboration ALISKIREN

Metabolites for CHEMBL1639

Open in full screen

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL1639. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL286 Renin Homo sapiens 1.000
CHEMBL2046264 Renin Macaca fascicularis 1.000
CHEMBL6056 Renin Callithrix jacchus 1.000

10uM


ChEMBL_ID Target Name Organism Score
CHEMBL286 Renin Homo sapiens 1.000
CHEMBL2046264 Renin Macaca fascicularis 1.000
CHEMBL6056 Renin Callithrix jacchus 1.000

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
551.8 551.3934 3.29 19 146.13 BASE


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
7 4 1 9 6 2


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
12.54 9.78 2.79 .12 1 39 0.19

Structural Alerts

There are 4 structural alerts for CHEMBL1639. To view alerts please click here.

Compound Cross References

ATC C - CARDIOVASCULAR SYSTEM
C09 - AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C09X - OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C09XA - Renin-inhibitors
C09XA02 - aliskiren

ChemSpider ChemSpider:UXOWGYHJODZGMF-QORCZRPOSA-N
DailyMed aliskiren hemifumarate
Wikipedia Aliskiren

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL1639



BindingDB 17950
Brenda 54356 1609
ChEBI 601027
DrugBank DB09026
DrugCentral 119
eMolecules 31229123
FDA SRS 502FWN4Q32
Guide to Pharmacology 4812
Human Metabolome Database HMDB0015387
IBM Patent System 98E3E9E5FC206E6632289E2138A740ED
LINCS LSM-2653
Mcule MCULE-6209020635
MolPort MolPort-006-167-755
Nikkaji J1.947.312K
PDBe C41
PharmGKB PA143487910
PubChem 5493444
PubChem: Thomson Pharma 14763777 14886049
SureChEMBL SCHEMBL455490
ZINC ZINC000004393164

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/UXOWGYHJODZGMF-QORCZRPOSA-N spacer
spacer